Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (5490)	1/20/2002 1:08:04 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

I strongly agree with you. The clincher, IMO, is the House Panel investigation. That event suggests that the House may well be in possession of convincing evidence of fraud; and wants to be seen as being a little more proactive than the government was in the Enron case. If this wasn't a fraud from the outset, why would IMCL sell any rights to Erbitux after Phase III was complete but before the NDA filing. Even the means of BMY investing in Erbitux now seems primarily a ploy attempting to let the Waksals get filthy rich even while in possession of undisclosed, material, adverse information. Clearly, one can stubbornly hope that C225 will ultimately be approved. I suspect that it's more likely that some of the IMCL principals will see jail time; and that C225 has been a cruel sham. All just in my opinion based upon the facts and events reported in the media, Ian